MedPath

Study of effects of Naltrexone treatment in alcohol dependent patients and influence by genotypes.Naltrexone is an FDA approved medication for treating alcohol dependence

Phase 4
Conditions
Health Condition 1: null- Alcohol Dependence Syndrome
Registration Number
CTRI/2017/12/010848
Lead Sponsor
avina Suresh
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1.ICD 10 criteria for alcohol use disorder.

2.Alcohol use disorder male subjects between the age group 18 to 60 years.

3.Abstinence from alcohol and other substances for 3-7 days.

4.Ability to provide informed consent.

5. One or more relatives or significant others who are willing to encourage medication therapy, adherence and provide follow-up information if contacted by research staff.

Exclusion Criteria

1.Major psychiatric disorder (i.e, schizophrenia, bipolar disorder, seizure disorder, alcohol induced psychotic disorder or dementia).

2.Advanced neurological, cardiovascular, renal, or hepatic disease; active tuberculosis or current febrile illness.

3.AIDS defining illness.

4.Significant laboratory abnormality (alanine aminotransferase/aspartate aminotransferase [ALT/AST] levels of greater than 5 times the top reference limit).

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The primary outcome measure will be the occurrence of relapse, that is, presence of heavy drinking on a single day as defined by 5 or more standard drinks during any given week of the trial measured by Time-Line Follow-Back(TLFB)Timepoint: Every 2 weeks till the end of 12 weeks
Secondary Outcome Measures
NameTimeMethod
Other outcome measures will be the time taken to relapse, number of heavy drinking days (as defined by more than 5 drinks/day for males), number of drinks per heavy drinking day as measured by the Time-Line Follow Back method and Obsessive Compulsive Drinking Scale measure, craving measured by obsessive compulsive drinking scaleTimepoint: At end of 12 weeks
© Copyright 2025. All Rights Reserved by MedPath